GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

DND PharmaTech 347850.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

37,950

+0.53%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About DND PharmaTech

Its shares trade on KOSDAQ under the ticker 347850.KQ. It has been listed since 2 May 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩4.30bn and a net loss of ₩23.55bn. At that date it held total assets of ₩97.54bn and shareholders' equity of ₩79.49bn.

DND PharmaTech Inc is a KR-based company operating in industry. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2024-05-02. DND Pharmatech Inc is a Korea-based clinical-stage biotech company mainly engaged in the research and development in medicines. The firm's product pipeline mainly focuses on indications including metabolic disease, neurodegenerative and fibrotic diseases. In addition, the Company is engaged in the research and development of therapeutic medicines used for diabetes, obesity and nonalcoholic steatohepatitis as well as others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
2 May 2024

Leadership

Pay as last reported

  • Mr. Seulki LeeChairman, Chief Executive Officer, Co-Founder, since 2023
  • Mr. Sungmook LimCo-Founder, Executive Director-R&D
  • Ms. Valina DawsonCo-Founder-Valted Seq, since 2023
  • Mr. Kang Choon LeeCo-Founder
  • Mr. Martin PomperCo-Founder

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • DND PharmaTech Inc focuses on metabolic disease research with a strong pipeline in Korea.
  • The company's clinical-stage biotech operations target neurodegenerative and fibrotic diseases effectively.
  • Seongnam, Gyeonggi-Do serves as a strategic hub for DND PharmaTech's R&D activities.

Weaknesses

  • DND PharmaTech Inc's IPO on 2 May 2024 indicates limited market experience.
  • The company's product pipeline is concentrated in specific therapeutic areas like diabetes.
  • Korea-based operations may face challenges in global market expansion.

Opportunities

  • The growing demand for diabetes treatments in Korea presents significant market potential.
  • Nonalcoholic steatohepatitis research aligns with rising global health priorities.
  • Korea's biotech sector growth offers collaborative opportunities for DND PharmaTech.

Threats

  • Regulatory hurdles in Korea could delay clinical-stage drug approvals.
  • Competition in the metabolic disease segment may intensify with new entrants.
  • Global economic downturns might reduce investment in biotech R&D funding.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.